May 28, 2024
8th BOSTON BIOTECHNOLOGY SUMMIT™ The Boston Paris Biotechnology Summit™ 2024, a key in-person meeting, also Live Streamed internationally brought Two Hundred (n=200) biopharmaceutical professionals [50% CEO and C-level Executives] to CIC CAMBRIDGE, 02142 Cambridge MA, 15 May 2024 to discuss the Economy & Investment, showcased Award-Winning...
June 8, 2023
Summit Mission An exclusive, Trans-Atlantic bridge designed to foster innovative synergies between biotech and pharma companies, healthcare-focused cities, and regional clusters, institutional, philanthropic and strategic investors. The Summit’s intent is to spark projects, their financings and strategic deals to solve unmet medical needs...
July 20, 2022
Selected Projects listed in alphabetical order: [ACTICOR-BIOTECH, Paris, France] US Medical Executive for Acticor BiotechDeveloping Glenzocimab, a humanized monoclonal antibody fragment directed against platelets glycoprotein VI (GPVI). Primary Indication = Stroke.ACTISAVE phase II/III Study [(NCT05070260] ongoing.Please refer to : www.acticor-biotech.com [DECOY...
January 6, 2022
[ACTICOR-BIOTECH, Paris, France] US Operations’ Collaboration [Press Release] November 4, 2021 at 06:30 pm CET – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, today announces that the U.S Food and Drug Administration (FDA) has provided clearance for...
November 8, 2021
Shahin Gharakhanian had the honor to accept on behalf of ACTICOR-BIOTECH – the PRIX GALIEN MEDSTARTUP 2021 – Award in the «collaboration» category recognizing joint work with the Memorial Hermann Hospital in Houston, Tx. Ceremony held at the Alexandria Life Sciences Center in New York 28 Oct. 2021. We are developing Glenzocimab, a humanized...
October 12, 2021
Prevention of Covid-19 Transmission Beyond the Needle: DCOY101, a novel antiviral fusion peptide-based prophylactic nasal spray. Barbara Hibner*, Peter Marschel*, Frederick E. Pierce II*, Shahin Gharakhanian** *Research & Development Program Team, **Scientific Advisory Board, DECOY Therapeutics, CAMBRIDGE MA, USA. [Contact:...
October 22, 2020
Summit Full Recording @ YouTube: http://youtu.be/wGFzVBq7byg Summit Synopsis: READ HERE Summit Website:www.bostonbiotechnologysummit.com
April 3, 2020
Cambridge MA, 02.03.2020. Stroke is listed as the 2nd cause of mortality worldwide according to the World Health Organization. ACTICOR-BIOTECH [CEO: Dr Gilles AVENARD], a leading, fully-funded, PARIS-based, biotechnology company is assessing its novel agent ACT017 as an add on therapy to Standard of Care in AIS: Acute Ischemic Stroke. This year Acticor-Biotech...